Tom Hudson, AbbVie SVP of R&D and CSO
October 31, 2022 07:28 AM EDT
R&D

Ab­b­Vie dis­cards PhI­Ib au­toim­mune drug from 10-year-old dis­cov­ery pact, cit­ing chron­ic tox­i­col­o­gy study

Amber Tong

When Ab­bott spun out its R&D group in­to Ab­b­Vie back in 2013, it al­so hand­ed off a drug dis­cov­ery deal that it had struck just …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times